Phoenix, Arizona, August 3, 2026: BioLab Holdings, Inc. has announced the publication of a peer-reviewed real-world evidence (RWE) study demonstrating promising clinical outcomes for its Membrane Wrap™ human amniotic tissue membrane in the treatment of complex pressure ulcers. Published in the International Journal of Tissue Repair, the multicenter pilot feasibility study evaluated Membrane Wrap™ in combination with standard of care (SOC) compared with standard wound care alone, highlighting the potential of placental-based regenerative therapies to improve healing outcomes in patients with chronic wounds. The study analyzed de-identified electronic health record data from the U.S. Wound Registry and Intellicure database, involving 182 patients across multiple healthcare settings. Results showed that 63.7% of patients treated with Membrane Wrap™ plus standard care were classified as healing or healed, compared with 48.4% of patients receiving standard care alone. The findings further strengthen BioLab’s growing body of clinical evidence supporting advanced wound care technologies designed to enhance tissue restoration and improve patient outcomes.
Real-World Evidence Demonstrates Improved Healing Outcomes
The newly published study represents one of BioLab Holdings’ ongoing efforts to generate meaningful real-world clinical evidence supporting the use of advanced regenerative therapies in challenging wound care settings. Researchers conducted a multicenter retrospective matched-cohort analysis using data collected from patients treated across multiple healthcare facilities and geographic regions throughout the United States. The study compared outcomes in 91 patients receiving Membrane Wrap™ alongside standard wound care with 91 matched patients treated with standard care alone. Investigators reported significantly higher healing rates among patients treated with the placental-based tissue membrane, supporting its potential role as an adjunctive therapy for managing complex pressure ulcers. Pressure ulcers continue to represent a major healthcare challenge, particularly among elderly individuals, patients with limited mobility and those living with multiple chronic medical conditions. Researchers also noted that the global burden of pressure ulcers has increased substantially over recent decades, reinforcing the need for innovative treatment strategies supported by robust clinical evidence.
Clinical Research Expands Advanced Wound Care Portfolio
The publication reflects BioLab Holdings’ broader commitment to strengthening the scientific foundation for its Cellular, Acellular and Matrix-like Products (CAMPs) portfolio through clinical trials and real-world research. Company leadership emphasized that generating high-quality evidence enables healthcare providers to make informed treatment decisions while supporting broader adoption of regenerative wound care technologies. Building upon the latest publication, BioLab continues advancing multiple clinical development programs evaluating next-generation regenerative products. Enrollment is currently underway in the CAMPR-II clinical trial, investigating Membrane Wrap Hydro™ and Microlyte™ for the treatment of diabetic foot ulcers and venous leg ulcers. Meanwhile, the BIOMOHS trial is progressing through Institutional Review Board approval before patient enrollment begins, while the CAMP RWE study has advanced into the statistical analysis phase. Together, these studies are expected to provide additional evidence supporting the clinical value of regenerative tissue technologies across a broad spectrum of chronic wound indications.
Regenerative Medicine Supports Future Wound Care Innovation
The latest findings reinforce the expanding role of placental-based regenerative medicine in addressing difficult-to-heal wounds that place significant clinical and economic burdens on healthcare systems worldwide. As chronic wounds become increasingly prevalent due to aging populations, diabetes and other chronic diseases, clinicians continue seeking therapies capable of accelerating tissue repair while improving healing consistency. BioLab Holdings believes that continued investment in peer-reviewed clinical research, real-world evidence generation, and innovative regenerative technologies will help advance evidence-based wound management while improving patient quality of life. By combining scientific validation with ongoing product development and commercialization, the company continues positioning its Membrane Wrap™ platform as an important component of modern advanced wound care, supporting physicians with clinically validated treatment options that promote tissue restoration and improved long-term patient outcomes.
SOURCE: BioLab Holdings press release